Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + trastuzumab + XELOX in resectable HER2-positive gastric or gastroesophageal junction adenocarcinoma
CTR20201997Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, trastuzumab, capecitabine, oxaliplatin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20201997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201997.